排序方式: 共有8条查询结果,搜索用时 0 毫秒
1
1.
2.
患者 女,55岁.体检时发现腹腔占位,无腹痛、腹胀,无畏寒发热,无恶心、呕吐,无腹泻.查体:腹部无明显阳性体征.实验室检查:肝功能正常,肿瘤标志物均正常. CT扫描(图1~4)示:肝尾状叶见团状低密度影,大小约10.0 cm×5.9 cm×7.4 cm,CT值约-65 HU,其内见不规则絮状软组织密度影,CT值约20 HU,病灶与肝左叶界限不清,增强后其内絮状软组织密度不均匀强化.超声检查示:肝内可见1个稍强回声团,主要位于肝左叶,约124 mm×64 mm,边界清,内回声不均匀,后方回声轻度衰减,CDFI显示未见明显血流信号. 相似文献
3.
4.
脑水肿的发生机制十分复杂,细胞内Ca2+超载、自由基损害、细胞膜Na+,K+-ATP酶活性降低等均与脑水肿的形成相关,但这些机制并不能很好地解释脑水肿的发生。近年来分子水平上水通道蛋白4(AQP4)的研究为探索脑水肿的发生机制带来了突破性进展。AQP4参与脑水肿的形成。AQP4基因沉默降低了AQP4的表达并能减轻脑水肿的程度。就AQP4基因沉默对脑水肿的影响及影像改变进行综述,以期为脑水肿的诊治提供有效的理论依据。 相似文献
5.
我院从1992年1月至1993年10月,对顽固性心衰患者102例伍用流甲丙脯酸(CPT)和酚妥拉明进行治疗,取得了满意疗效,现报告如下。临床资料与方法一般资料:顽固性心衰病人102例,其中男86例,女16例;年龄18-80岁,平均42岁。其中肺源性心脏病48例,风湿性心脏病17例,高血压性心脏病24例,冠状动脉硬化性心脏病13例。治疗方法:本组除治疗原发病外,并用抗生素控制感染,纠正电解质和酸碱失衡,用洋地黄和利尿剂等处置,心衰均无改善者称顽因性心衰。口服流甲丙脯酸12.sing,三次/日,酚妥拉明109加10%葡萄糖200Inl静脉滴入,一次/… 相似文献
6.
7.
8.
BACKGROUND:A number of studies have shown that there are many inducible methods by which bone marrow mesenchymal stem cells can differentiate into hepatocytes, but the specific molecular mechanism is unclear yet.
OBJECTIVE:To review the programs and underlying mechanisms by which bone marrow mesenchymal stem cells differentiate into hepatocytes.
METHODS:A computer-based online search of CNKI, VIP, WanFang and PubMed databases was performed to retrieve articles about directional differentiation of bone marrow mesenchymal stem cells into hepatocytes published between 2004 and 2015. The key words were “hepatocyte (-like) cells, bone marrow mesenchymal stem cells, differentiation” in Chinese and English, respectively. Finally, 62 articles were included in result analysis.
RESULTS AND CONCLUSION:There are many programs for hepatic differentiation of bone marrow mesenchymal stem cells, but the specific molecular mechanism is still unclear. Many studies mainly focus on Notch signaling pathway, Wnt/β-catenin signaling pathway, P38 signal pathway, miR-122 and effect of calcium ions. Bone marrow mesenchymal stem cells that can be induced to differentiate into mature hepatocytes provide an ideal cellular source for hepatocyte transplantation and artificial liver, which is proposed to be a new strategy for clinical treatment of end-stage liver disease. 相似文献
1